To consider and approve the Unaudited Financial results along with the Limited Review Report for the quarter ended 30th June, 2026, Request received for withdrawal of application for reclassification ....

Date: 07th August, 2026 To, To, The Manager (Listing) Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai – 400051 BSE Scrip Code: 506260 NSE Symbol: ANUHPHR; Series: EQ Subject: Outcome of Board Meeting dated, 07th August, 2026. Dear Sir/Madam, Pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors of Anuh Pharma Limited (the Company) at its meeting held today, Friday, 07th August, 2026, has inter alia considered and approved the following: 1. The Un-Audited Financial Results along with Limited Review Report for the quarter ended 30th June, 2026 (annexed as Annexure – A); 2. The requests received from the following Shareholders forming part of Promoter Group of the Company seeking withdrawn their application for reclassification and shall continue to remain a part of Promoter Group of the Company. Number of Sr % of Name Equity shares No. shareholding held 1. Vikram Kirtilal Shah 200 0.00 2. Kiran Piyush Shah 15,388 0.02 3. Kinjal Siddharth Jhaveri 8,16,160 0.81 TOTAL 8,31,748 0.83 The Withdrawal request has been annexed as Annexure – B; 3. The Adoption of revised Policy on Related Party Transactions. The said policy is available on the website of the Company www.anuhpharma.com. The Meeting of the Board of Directors commenced at 01:00 p.m. and concluded at 05:15 p.m. Kindly take the above on your records. Thanking you, Yours faithfully, FOR ANUH PHARMA LIMITED MANAN VADHAN COMPANY SECRETARY & COMPLIANCE OFFICER Encl: a/a Annexure - A ANUH PHARMA LTD. CIN: L24230MH1960PLC011586 Regd. Office: 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai -40~018 Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com;Website:www.anuhpharma.com UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026 (Rs. in Lakhs) 3 months 3 months 3 months 12 months ended ended ended ended Sr. 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Particulars Audited Unaudited (Refer Note Unaudited Audited No.5) (1) (2) (3) (4) (5) (6) I Revenue from operations 19,381.04 20,211.72 18,647.94 77,165.74 II Other income (Refer Note No-6) 307.67 (125.46) 338.84 435.56 Ill Total Revenue (I + II) 19,688.71 20,086.26 18,986.78 77,601.30 IV Expenses: Cost of materials consumed 15,996.42 14,071.39 12,390.50 51,044.32 Purchases of Stock-in-Trade 414.33 282.87 2,649.64 7,919.67 Changes in inventories of finished goods, work-in- (1,579.88) 768.33 222.26 1,002.09 I oroqress and Stock-in-Trade Employee benefits expense 735.16 634.93 629.79 2,630.33 Finance costs 0.35 10.58 21.13 47.23 Depreciation and amortization expense 243.28 300.29 251.50 1,138.22 Other expenses 2,1 86.24 2,465.92 1,726.65 8,397.30 Total expenses (IV) 17,995.90 18,534.31 17,891.47 72,179.16 v Profit I (Loss) before exceptional and Items and 1,692.81 1,551.95 1,095.31 5,422.14 tax (Ill -IV) VI Exceptional items - - - - VII Profit I (Loss) before tax (V -VI) 1,692.81 1,551.95 1,095.31 5,422.14 VIII Tax expenses: (1) Current tax 413.20 496.10 249.00 1,518.10 (2) Deferred tax 137.12 (91.73) 16.19 (184.39) (3) Income tax of earlier years - (20.56) - (16.18) Total Tax expenses (VIII) 550.32 383.81 265.19 1,317.53 IX Profit/(Loss) after Tax (VII-VIII) 1,142.49 1,168.14 830.12 4,104.61 x Other Comprehensive Income (i) items that will not be reclassified to profit or loss (4.40) (39.22) (8.11) 24.73 (ii) Income Tax relating to the items that will not be 1.11 9.88 2.04 (6.22) reclassified to profit or loss (ii) Items that will be reclassified to profit or loss - - Total Other Comprehensive Income (3.29) (29.34) (6.07) 18.51 (net of Tax) (Xl (net of Tax) Total Comprehensive Income for the period (IX XI + X) (Comprising Profit I (Loss) and Other 1,139.20 1,138.80 824.05 4,123.12 Comprehensive Income for the period) Paid up Equity Share Capital (Face value Rs. 5/-each) (Refer note no. 5,011.20 5,011.20 2,505.60 5,011.20 Other Equity - - - 30,211.04 (excluding revaluation reserves) Earnings per equity share XII (For respective periods) (In Rs.) (Refer note no. 4) (1) Basic 1.14 1.17 0.83 4.10 (2) Diluted 1.14 1.17 0.83 4.10 See accompanying notes to the financial results Notes:- 1. These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act 2013 ('the Act) read with the Companies (Indian Accounting Standards) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities Exchange Board ofindia ("SEBI'') (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended). 2. These unaudited financial results for the quarter ended 30th June, 2026 were reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on 07th August, 2026 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the Statutory Auditors of the Company. 3. Other Financial indicators (Rs. in Lakhs) 3 months 3 months 3 months 12 months Particulars ended ended ended ended 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Audited (Refer Unaudited Unaudited Audited Note No.5) EBITDA 1,936.44 1,862.82 1,367.94 6,607.59 % ofEBITDA Margin 9.99 9.22 7.34 8.56 EBITDA 1,814.45 2,356.40 1,008.64 6,784.24 (Adjusted to FOREX Gain I Loss and Other Income) % of Adjusted EBITDA Margin 9.36 11.66 5.41 8.79 4. During the quarter ended September 30, 2025 the shareholders of the company have approved, through the postal ballot, the issuance of the bonus shares, in the proportion of 1: 1 i.e. 1( one) bonus equity share of Rs 5 each for every 1( one) fully paid up equity share held on as on the record date. Accordingly, the company has allotted 5,01,12,000 as a bonus shares on 16th July, 2025 by utilization of General reserves. All the shares and per share information in the financial results reflect the effect of the bonus share issuance. 5. The figures of the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year upto 31st March, 2026 and the unaudited published year to date figures upto 3 lst December, 2025 being the date of end of the third quarter of financial year respectively which were subject to limited review. 6. Other income for the quarter ended 31st March 2026 includes mark to market loss on investment of~ .189.7 7 Lakhs. 7. The Company does not have any subsidiary/associate/joint ventures as on 30th June 2026. 8. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided. 9. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period. For Anuh Pharma Ltd. Ritesh Shah Place : Mumbai Joint Managing Director Date : 07th August, 2026 (DIN: 02496729) 111 (A) MAHATMA GANDHI ROAD, JAYANTILAL THAKKAR & CO. FORT, MUMBAI -400 023. CHARTERED ACCOUNTANTS Telephones: (91-22) 2265 8800 (91-22) 2265 ~900 E-Mails jtco23@jtco.co.in office@jtco.co.in Website : www.jtco.co.in Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended TO THE BOARD OF DIRECTORS Anuh Pharma Limited 1. We have reviewe [Showing first 8,000 characters — download PDF for full document]